small molecule

VOYDEYA

DANICOPAN

Loss of exclusivityAugust 2038latest FDA-listed patent expiry

CompanyAlexion Pharmaceuticals →See this company's full patent-cliff portfolio

Drug detail

Brand name	VOYDEYA
Active ingredient	DANICOPAN
Strength	50MG
Dosage form	TABLET
Route	ORAL
Modality	Small molecule
FDA approval	March 2024
Marketing status	RX

Listed patents

Patent	Expires	Type
12076319	August 2038	use U-3933
9796741	February 2035	substance

Regulatory exclusivity

Code	Expires
ODE-476	March 2031
NCE	March 2029

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

Drug detail

Listed patents

Regulatory exclusivity

More from Alexion Pharmaceuticals